# Astellas Pharma Global Development, Inc.: Phase 2 study closed enrollment, 393 enrolled (Pancreatic Cancer, Metastatic Pancreatic Cancer)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Astellas Pharma Global Development, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer |
| NCT ID | NCT03816163 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma |
| Intervention types | drug |
| Target enrollment | 393 |
| Site countries | United States, Australia, Brazil, China, France, Ireland, Italy, Japan, Mexico, South Korea, Spain, Taiwan |
| Posted | 2019-01-25 |
| Planned start | 2019-03-15 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-14 |
| Last update posted | 2026-10-14 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 393 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03816163). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.